Allogene Therapeutics Inc (ALLO)

$1.74 -0.13 (-6.95%)
Market Cap 413.50M
Revenue (ttm) 20,000.00
Net Income (ttm) -257.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,287,950.01%
Debt to Equity Ratio 0.00
Volume 8,029,600
Avg Vol 4,368,434
Day's Range N/A - N/A
Shares Out 224.73M
Stochastic %K 56%
Beta 0.51
Analysts Strong Sell
Price Target $7.38

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 2700
Address:
210 East Grand Avenue, South San Francisco, United States
tisuu
tisuu Feb. 3 at 7:19 PM
$ALLO BUY BUY buy
0 · Reply
Ren_Stimpy
Ren_Stimpy Feb. 3 at 4:31 PM
Can the bio-nerds from $ALLO $ATON $PGEN $MRNA tell me why $HURA is so hated? Can't find the red flags. What am I missing? https://ir.tuhurabio.com/news-events/presentations
0 · Reply
tisuu
tisuu Feb. 3 at 3:00 PM
$ALLO buy now. Not going to wait for you when it hits $2.20
0 · Reply
SmurfVillage
SmurfVillage Feb. 3 at 1:49 PM
$ALLO We going 2.20+
0 · Reply
tisuu
tisuu Feb. 3 at 3:48 AM
$ALLO breakout?
0 · Reply
DimebagDarrell_
DimebagDarrell_ Feb. 3 at 2:40 AM
$ALLO HYFR!
0 · Reply
Mr_JokeR
Mr_JokeR Feb. 3 at 12:19 AM
$ALLO feeling like adding another 5k shares...
0 · Reply
ils85
ils85 Feb. 2 at 6:54 PM
$ALLO added 3 plus next
1 · Reply
Booker1
Booker1 Feb. 2 at 6:38 PM
$ALLO In at $1.74 Lets go, one of the best setups this week!
0 · Reply
BioBuddha
BioBuddha Feb. 1 at 6:02 PM
$ALLO by June this will either be in double digits or below 1. The likelihood of double digits is pretty high.
0 · Reply
Latest News on ALLO
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Jan 8, 2026, 8:30 AM EST - 27 days ago

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Dec 15, 2025, 5:39 PM EST - 7 weeks ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

CLLS

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Nov 10, 2025, 8:30 AM EST - 3 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T

Nov 7, 2025, 6:08 PM EST - 3 months ago

Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T

Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 12:16 AM EST - 3 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Nov 3, 2025, 9:04 AM EST - 3 months ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Oct 30, 2025, 8:30 AM EDT - 3 months ago

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Oct 4, 2025, 12:22 AM EDT - 4 months ago

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 27, 2025, 8:30 AM EDT - 5 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 14, 2025, 3:02 PM EDT - 6 months ago

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:13 PM EDT - 6 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 6, 2025, 8:30 AM EDT - 6 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Aug 1, 2025, 8:30 AM EDT - 6 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025, 10:45 AM EDT - 8 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 29, 2025, 3:37 PM EDT - 8 months ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 28, 2025, 9:43 AM EDT - 9 months ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025, 5:17 PM EDT - 9 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:47 PM EDT - 9 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025, 4:05 PM EDT - 9 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025, 8:30 AM EDT - 9 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:12 AM EDT - 10 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Apr 7, 2025, 8:30 AM EDT - 10 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 11:56 PM EDT - 11 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 13, 2025, 4:02 PM EDT - 11 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 10:52 AM EST - 1 year ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 25, 2025, 4:10 PM EST - 1 year ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Feb 24, 2025, 10:53 PM EST - 1 year ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Feb 13, 2025, 4:30 PM EST - 1 year ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 28, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Dec 12, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:59 PM EST - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 26, 2024, 11:39 PM EDT - 1 year ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

tisuu
tisuu Feb. 3 at 7:19 PM
$ALLO BUY BUY buy
0 · Reply
Ren_Stimpy
Ren_Stimpy Feb. 3 at 4:31 PM
Can the bio-nerds from $ALLO $ATON $PGEN $MRNA tell me why $HURA is so hated? Can't find the red flags. What am I missing? https://ir.tuhurabio.com/news-events/presentations
0 · Reply
tisuu
tisuu Feb. 3 at 3:00 PM
$ALLO buy now. Not going to wait for you when it hits $2.20
0 · Reply
SmurfVillage
SmurfVillage Feb. 3 at 1:49 PM
$ALLO We going 2.20+
0 · Reply
tisuu
tisuu Feb. 3 at 3:48 AM
$ALLO breakout?
0 · Reply
DimebagDarrell_
DimebagDarrell_ Feb. 3 at 2:40 AM
$ALLO HYFR!
0 · Reply
Mr_JokeR
Mr_JokeR Feb. 3 at 12:19 AM
$ALLO feeling like adding another 5k shares...
0 · Reply
ils85
ils85 Feb. 2 at 6:54 PM
$ALLO added 3 plus next
1 · Reply
Booker1
Booker1 Feb. 2 at 6:38 PM
$ALLO In at $1.74 Lets go, one of the best setups this week!
0 · Reply
BioBuddha
BioBuddha Feb. 1 at 6:02 PM
$ALLO by June this will either be in double digits or below 1. The likelihood of double digits is pretty high.
0 · Reply
Merlintrader
Merlintrader Jan. 31 at 9:20 PM
$ALLO https://www.merlintrader.com/allo-allogene-therapeutics-inc/
1 · Reply
Dongla
Dongla Jan. 31 at 12:39 PM
$ALLO Does anyone know what’s driving the recent move in $ALLO?
1 · Reply
Southshd
Southshd Jan. 31 at 11:51 AM
$ALLO Nice way to close out the week! Lets get a press release with some good results Monday so we can get above and stay above $2! 200k shares Long and Strong GL
0 · Reply
GoCubsGo1124
GoCubsGo1124 Jan. 31 at 1:31 AM
$ALLO just showed up on my scanner. Worth it?
0 · Reply
ils85
ils85 Jan. 30 at 8:47 PM
$ALLO loading
0 · Reply
selftaught
selftaught Jan. 30 at 8:46 PM
$ALLO I hope this thing goes higher but I made my money. Good luck everyone
1 · Reply
selftaught
selftaught Jan. 30 at 8:32 PM
$ALLO Compare to the psychology chart. Tell me where we are going next. Volume tanked
1 · Reply
selftaught
selftaught Jan. 30 at 8:30 PM
$ALLO Im out at 1.82
0 · Reply
GangsterX
GangsterX Jan. 30 at 7:54 PM
$ALLO i hate this type of run... pathetic shix.. cant hold the price above 1.90... they did it 2x....
2 · Reply
selftaught
selftaught Jan. 30 at 7:51 PM
$ALLO nice support at 1.74
0 · Reply
Unburdened
Unburdened Jan. 30 at 7:50 PM
$ALLO 12M shares traded. Really interesting. Feels like something is brewing. Three times the normal volume so far today.
0 · Reply
selftaught
selftaught Jan. 30 at 7:41 PM
$ALLO back up again lets see if we get back over 1.82
0 · Reply